InvestSMART

Argenica Therapeutics Limited (ASX: AGN) - Announcements

- Current share price for AGN : $0.110

ASX company news and announcements for Argenica Therapeutics Limited (AGN) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Argenica Therapeutics Limited (AGN) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Argenica Therapeutics Limited (AGN), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Argenica Therapeutics Limited (AGN)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$14 Quarterly Activities/Appendix 4C Cash Flow Report 31 Oct 2025 9:16AM $0.280 $0.110 fallen by 60.71%
$14 Investor Presentation - Cannacord Dug & Device Conference 21 Oct 2025 9:04AM $0.270 $0.110 fallen by 59.26%
$14 Notification regarding unquoted securities - AGN 20 Oct 2025 1:16PM $0.285 $0.110 fallen by 61.40%
$14 Phase 2 Trial Promising Improvements in Functional Outcomes 15 Oct 2025 8:28AM $0.240 $0.110 fallen by 54.17%
$14 Notice of Annual General Meeting/Proxy Form 13 Oct 2025 2:09PM $0.245 $0.110 fallen by 55.10%
$14 ASX Small Caps Conference Presentation 24 Sep 2025 10:49AM $0.285 $0.110 fallen by 61.40%
$14 Date of AGM & Closing Date for Director Nominations 17 Sep 2025 8:57AM $0.310 $0.110 fallen by 64.52%
$14 Change in substantial holding 4 Sep 2025 8:17AM $0.280 $0.110 fallen by 60.71%
$14 Investor Webinar 3 Sep 2025 9:37AM $0.645 $0.110 fallen by 82.95%
$14 Investor Presentation 3 Sep 2025 9:35AM $0.645 $0.110 fallen by 82.95%
$14 Topline Phase 2 Trial Results of ARG-007 in AIS Patients 3 Sep 2025 9:34AM $0.645 $0.110 fallen by 82.95%
$14 Topline Phase 2 Trial Results of ARG-007 in AIS Patients 3 Sep 2025 9:34AM $0.645 $0.110 fallen by 82.95%
$14 Trading Halt 1 Sep 2025 9:01AM $0.645 $0.110 fallen by 82.95%
$14 Trading Halt 1 Sep 2025 9:01AM $0.645 $0.110 fallen by 82.95%
$14 Appendix 4G & Corporate Governance Statement 28 Aug 2025 5:06PM $0.640 $0.110 fallen by 82.81%
$14 Appendix 4E & Annual Report to 30 June 2025 28 Aug 2025 5:05PM $0.640 $0.110 fallen by 82.81%
$14 Argenica Receives IND Feedback From FDA 14 Aug 2025 9:08AM $0.705 $0.110 fallen by 84.40%
$14 Bioshares Biotech Summit Presentation 8 Aug 2025 9:11AM $0.685 $0.110 fallen by 83.94%
$14 Argenica Appoints Vice President of Regulatory Affairs 6 Aug 2025 8:15AM $0.675 $0.110 fallen by 83.70%
$14 Ceasing to be a substantial holder from IFL 23 Jul 2025 3:48PM $0.690 $0.110 fallen by 84.06%
$14 Quarterly Activities/Appendix 4C Cash Flow Report 23 Jul 2025 8:42AM $0.655 $0.110 fallen by 83.21%
$14 Cleansing Notice 9 Jul 2025 5:04PM $0.690 $0.110 fallen by 84.06%
$14 Application for quotation of securities - AGN 9 Jul 2025 5:03PM $0.690 $0.110 fallen by 84.06%
$14 Notification of cessation of securities - AGN 9 Jul 2025 5:02PM $0.690 $0.110 fallen by 84.06%
$14 Application for quotation of securities - AGN 9 Jul 2025 5:02PM $0.690 $0.110 fallen by 84.06%

26 - 50 of 288 results

Page 2 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.